- Home
- MBWM vs NUVB Comparison
MBWM vs NUVB Comparison
Compare MBWM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBWM
- NUVB
- Stock Information
- Founded
- MBWM 1997
- NUVB 2018
- Country
- MBWM United States
- NUVB United States
- Employees
- MBWM N/A
- NUVB N/A
- Industry
- MBWM Major Banks
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- MBWM Finance
- NUVB Health Care
- Exchange
- MBWM Nasdaq
- NUVB Nasdaq
- Market Cap
- MBWM 763.4M
- NUVB 837.0M
- IPO Year
- MBWM 1997
- NUVB N/A
- Fundamental
- Price
- MBWM $49.25
- NUVB $2.97
- Analyst Decision
- MBWM Buy
- NUVB Strong Buy
- Analyst Count
- MBWM 4
- NUVB 6
- Target Price
- MBWM $53.63
- NUVB $8.00
- AVG Volume (30 Days)
- MBWM 55.6K
- NUVB 4.7M
- Earning Date
- MBWM 10-14-2025
- NUVB 08-07-2025
- Dividend Yield
- MBWM 3.00%
- NUVB N/A
- EPS Growth
- MBWM N/A
- NUVB N/A
- EPS
- MBWM 5.03
- NUVB N/A
- Revenue
- MBWM $228,384,000.00
- NUVB $14,355,000.00
- Revenue This Year
- MBWM $10.34
- NUVB $332.80
- Revenue Next Year
- MBWM $11.93
- NUVB $360.12
- P/E Ratio
- MBWM $9.79
- NUVB N/A
- Revenue Growth
- MBWM 3.70
- NUVB 900.35
- 52 Week Low
- MBWM $37.76
- NUVB $1.54
- 52 Week High
- MBWM $52.98
- NUVB $3.46
- Technical
- Relative Strength Index (RSI)
- MBWM 60.30
- NUVB 66.52
- Support Level
- MBWM $47.37
- NUVB $2.57
- Resistance Level
- MBWM $50.23
- NUVB $3.08
- Average True Range (ATR)
- MBWM 1.26
- NUVB 0.18
- MACD
- MBWM 0.36
- NUVB 0.02
- Stochastic Oscillator
- MBWM 81.65
- NUVB 87.66
About MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.